Trial Profile
An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 13 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 13 Dec 2022 Planned primary completion date changed from 22 Dec 2022 to 22 Dec 2024.
- 25 Feb 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.